Advertisement

MRNA

Moderna, Inc.

Healthcare · USD

Set alert

Price alert · MRNA

All alert types
221.72 USD -1.04 -0.47%
As of Oct 30, 2026 Extended hours 221.50 -0.10%
Bid
221.57 × 1
Ask
221.70 × 1
217.22 Day range 227.53
22.36 52-week range 245.81
YTD
+651.85%
1 year
+687.92%
Open
221.11
Prev close
222.76
Mkt cap
88.52B
Vol
9.01M
Avg vol
21.28M
EPS
-7.98
P/E
0.00
Div yield
0.00%
More statistics
Low
217.22
High
227.53
Forward P/E
-48.35
Beta
1.09
Short ratio
1.86
Inst. own
80.55%
Dividend
0.00
Ex-div date
Earnings
Nov 6, 2026
50-d avg
180.72
200-d avg
85.67
1y target
138.37

5D chart

Chart tools
Interval
MRNA five-day price chart179.5191.5203.5215.5227.5Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
88.52B
Enterprise value
85.08B
Trailing P/E
0.00
Forward P/E
-48.35
PEG ratio
0.00
Price / sales
39.73
Price / book
13.08
EPS (TTM)
-7.98
Beta
1.09
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-141.43%
Revenue (TTM)
2.23B
Revenue growth
2.10%
Free cash flow
299.25M
Total cash
5.14B
Total debt
1.29B
Return on equity
-39.00%
Shares outstanding
399.24M
Short % of float
9.98%
50-day average
180.72
200-day average
85.67

Analyst view

Consensus: hold

Hold
Price target (mean) 138.37 -37.6% downside
Target (low)
45.00
Target (mean)
138.37
Target (high)
251.00
Ratings (0m) 23 4 buy · 16 hold · 3 sell
  • Strong buy1
  • Buy3
  • Hold16
  • Sell2
  • Strong sell1

Next earnings

Nov 6, 2026

Expected Nov 6, 2026. Consensus EPS estimate -1.35.

Earnings history

Financials — quick view

All financials
MRNA Revenue — quarterly 145.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRNA Net income — quarterly -782.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRNA EPS — quarterly -1.97
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MRNA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2026Sep 30, 2026-1.10———
Jul 31, 2026Jun 30, 2026-2.03-1.97+0.06+2.96%
May 1, 2026Mar 31, 2026-4.45-3.40+1.05+23.60%
Feb 13, 2026Dec 31, 2025-2.54-2.11+0.43+16.93%
Nov 6, 2025Sep 30, 2025-1.87-0.51+1.36+72.73%
Aug 1, 2025Jun 30, 2025-2.99-2.13+0.86+28.76%

Upgrades / downgrades

MRNA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026William BlairdownOutperformMarket Perform
Oct 26, 2026Piper SandlerreitOverweightOverweight
Oct 21, 2026TD CowenmainHoldHold
Oct 15, 2026Goldman SachsmainNeutralNeutral
Oct 7, 2026Morgan StanleymainEqual-WeightEqual-Weight
Sep 30, 2026CitigroupdownNeutralSell

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MRNA — it syncs with the Stock Master app.

Insider holders

MRNA insider holders
InsiderRelationLatest transactionDateShares held
AFEYAN NOUBAR BOGHOSDirectorSaleMay 20, 20260
BANCEL STEPHANE JChief Executive OfficerConversion of Exercise of derivative securityAug 5, 202622,215,800
HOGE STEPHENPresidentConversion of Exercise of derivative securitySep 14, 20261,718,080
HORNING SANDRADirectorConversion of Exercise of derivative securityApr 29, 202618,585
HUSSAIN SHAH ABBASDirectorSaleApr 30, 202612,066
KLINGER SHANNON THYMEOfficerConversion of Exercise of derivative securitySep 3, 202681,340

Institution ownership

MRNA institution ownership
Holder% heldSharesValueReported
FMR, LLC12.99%51,859,89111.50BJun 29, 2026
Blackrock Inc.7.66%30,599,4096.78BJun 29, 2026
Vanguard Capital Management LLC5.81%23,208,7925.15BJun 29, 2026
Capital World Investors5.58%22,276,9964.94BJun 29, 2026
BAILLIE GIFFORD & CO4.56%18,206,7784.04BJun 29, 2026
State Street Corporation3.94%15,726,1933.49BJun 29, 2026

Fund ownership

MRNA fund ownership
Holder% heldSharesValueReported
Growth Fund of America3.75%14,983,2293.32BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.84%11,331,6922.51BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.29%9,154,5102.03BJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.06%8,239,1751.83BAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.05%8,190,0721.82BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.30%5,187,9701.15BJun 29, 2026
Advertisement